NCT06452329Completed
A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
Retrospective Evaluation of Nivolumab in First-Line Unresectable Advanced or Metastatic Gastric Cancer (GC) and Gastroesophageal Junction Cancer (GEJC): A Non-interventional Observational Study in China
Source: ClinicalTrials.gov · Last updated 4 Dec 2025
Brief summary (registry, in English)
The purpose of this study is to collect and evaluate real-world data to enhance understanding of the effectiveness, and treatment patterns of first-line nivolumab treatment in patients with unresectable advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC) in China
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 260 (actual)
- First submitted
- 5 Jun 2024
- Start date
- 28 Feb 2024
- Primary completion date
- 29 Jul 2025
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT06452329
What you commit to
- Study type: Observational
- Participants enrolled: 260
- From 28 Feb 2024 to the primary completion date, 29 Jul 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Participants with primary malignancies other than unresectable advanced or metastatic GC/GEJC
Other
- Participants who participate in an interventional clinical trial in or before 1L nivolumab treatment for advanced/metastatic GC/GEJC
- Participants with known HER2 status positive
- Participants who investigator deems inappropriate for inclusion, for example clinical data was incomplete
Who the study is looking for
- Participants aged ≥ 18 years at date of first administration of nivolumab
- Confirmed diagnosis of unresectable advanced or metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC) (histologically or cytologically)
- Participants newly received nivolumab as first-line (1L) treatment between 15 June 2018 and 30 June 2023
- Participants with at least one tumor assessment after index date except for death or discontinuation due to Adverse Events
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tianjin Happy Life Technology Co., Ltd Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| - Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.